96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsFrequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.Assessing the performance of a computer-based policy model of HIV and AIDSIncidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USAProtease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.Projected survival gains from revising state laws requiring written opt-in consent for HIV testing.Routine HIV screening in Portugal: clinical impact and cost-effectiveness.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020AEffects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Long-term treatment of patients with HIV-1: the role of atazanavirCost-effectiveness of tenofovir as first-line antiretroviral therapy in India.PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.Trends in prevalence of diarrhoea, Kaposi's sarcoma, bacterial pneumonia, malaria and geohelminths among HIV positive individuals in Uganda.Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE studyActivity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label studyTenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studiesPharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the USThe clinical implications of antiretroviral pharmacogenomics.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.Atazanavir: simplicity and convenience in different scenarios.Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsulesLong-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infectionCrofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDSManagement of HIV-1 infection in adultsLong-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
P2860
Q24674939-F4D4E7B9-0E84-465C-B4B3-74B6BCA47158Q30379957-7097EE78-F276-4D70-A6C5-4029336A2BCAQ33776536-BE09200C-7BC8-45AD-B4C9-E0CA9D613815Q33918414-80577146-A979-4AA1-A852-1A91B1EE421CQ34115343-3CED2039-3978-45DC-B3D5-1FE05275AF7EQ34159702-2B374A64-3FB6-4A12-911F-2748AA854C06Q34393599-E86AAB92-DE76-45AF-8A0B-8AF1B7AA59CFQ34440857-14CE7B59-2F26-497D-BA27-0981DAB587B4Q34631149-38AD63F6-DF07-4FF7-B9CF-9E4B926A0E00Q34633457-B61BCBB5-B11E-4A13-B35D-4EB183CDF478Q34952722-FA983992-EF1E-4B6B-9CEF-EC88F2E3A311Q35007043-C18E9357-08FE-4818-B704-B4349B413A8BQ35075697-E6A51DE3-2243-4103-845A-AAB3F79B02BFQ35079510-176CC8DF-F68D-40B2-9961-A1270CE75A1BQ35163596-7BCCFF7B-955E-4C58-B0DC-F951438CFF55Q35168318-6600F9D6-73EA-4A1C-BABF-239DD64FD30AQ35244295-365CBDE0-641B-43B5-AE01-40F3F2CF9937Q35557219-7556ACB5-E768-41AD-907C-C66E42A5861CQ35575721-2EEEEEA9-8ECB-4910-8104-FAC239F7FFB9Q35722000-503B2983-5267-41DF-B2DC-27D7B9820EF2Q35737444-C9636F94-6A92-458A-876C-1AA3A1E28B47Q35903617-2549DCDE-A991-4595-8DCD-C4A7A44117D4Q35908862-E6B987E4-B75E-4EE6-B0C8-6C1758C9857EQ35912640-6A01EE1A-6ABE-49F8-9A1C-90837327E5E1Q35963960-E27D7408-4A21-4B16-944A-59DE23F34E38Q36094771-369D91F1-189F-44B7-A36D-0E068252B738Q36105831-D4256F63-3769-4657-82EB-C30E126B3398Q36204098-446B26BB-F3AC-4B45-92F7-1BAFB083B01AQ36425083-DF98196B-1E75-494C-9BCA-BBA943B425EAQ36479518-B93C70B3-4BAB-4C7B-8D54-49E84D0A0FB5Q36497078-B6F385F6-3190-4A39-AE97-D251C885D6F6Q36723780-A2E13C90-0B17-4EFC-8A4D-2CC68475ACD0Q36723853-8600B8F9-9233-4B78-AD2D-3E936DB69617Q36747289-663BF068-1C88-4830-B26B-E2A7D4748A3AQ36765802-78713337-6C3A-48C4-B3C8-D5CA9AA75EB0Q36926668-FCCDE7E9-B084-4636-80A8-5EBAC2FFA0F3Q36974067-087DB784-689C-44E8-8D59-BA4D806ED138Q37042269-B0CA288C-8B7E-4909-81A1-F790C637CCC6Q37061033-5764980E-EC00-47FB-8EA8-CF637D07A532Q37154865-539B88B5-DAA5-4D88-AE46-8A9B0B1CF54E
P2860
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
96-week comparison of once-dai ...... h multiple virologic failures.
@en
96-week comparison of once-dai ...... h multiple virologic failures.
@nl
type
label
96-week comparison of once-dai ...... h multiple virologic failures.
@en
96-week comparison of once-dai ...... h multiple virologic failures.
@nl
prefLabel
96-week comparison of once-dai ...... h multiple virologic failures.
@en
96-week comparison of once-dai ...... h multiple virologic failures.
@nl
P2093
P1433
P1476
96-week comparison of once-dai ...... h multiple virologic failures.
@en
P2093
Anna Rightmire
Claudia Rodriguez
Colin McLaren
Edwin DeJesus
Jeffrey Coco
Kenneth Lichtenstein
Linda Odeshoo
Margaret Johnson
Victoria Wirtz
P304
P356
10.1097/01.AIDS.0000216371.76689.63
P407
P577
2006-03-01T00:00:00Z